China National Pharmaceutical Group: Consistency evaluation of the specification of Vitamin B6 injection approved.

China National Pharmaceutical Group Corporation (Sinopharm) announced that its wholly-owned subsidiary, Sinopharm Rongsheng, has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The approval allows for an increase in the specification of Vitamin B6 injection from 1ml:0.1g and has passed the evaluation for consistency in generic drug quality and efficacy. Vitamin B6 injection is mainly used for the prevention and treatment of Vitamin B6 deficiency and other related indications. In 2024, the sales of this drug in public medical institutions nationwide are expected to be around 304 million yuan. As of now, the cumulative research and development investment in this project by Sinopharm Rongsheng is 4.085 million yuan. This approval is beneficial for the market expansion and sales of the product, but it will not have a significant impact on the company's current operating performance.